SimBioSys
  • Home
  • Technology
  • Solutions
    • TUMORSIGHT VIZ
    • TUMORSIGHT RISK
    • PHENOSCOPE

      CLINICAL SOLUTIONS

      • TumorSight Viz
      • TumorSight RISK

      RESEARCH SOLUTIONS

      • PhenoScope
  • Resources
  • About Us
    • Our Company
    • Our Team
    • Careers
      • Our Company
      • Our Team
      • Careers
Contact Us

Month: June 2023

SimBioSys June 16, 2023 ISMRM 2023, Publications

Radiologist validation of a multi-tissue breast segmentation convolutional neural net ensemble

We developed an ensembled suite of convolutional neural networks (core components of SimBioSys TumorSight) that segmented tumor and other tissues, in and around the breast (chest, adipose, gland, vasculature, skin). We sought to validate model results against the expertise of…

Continue
SimBioSys June 16, 2023 ASCO 2023

DCE-MRI-derived microvasculature mapping and outcome prediction in patients with breast cancer.

Here, we show how MV maps — computed from standard-of-care (SOC) imaging — improve upon ctDNA measurements in predicting pathologic complete response (pCR) following NAT as well as distant recurrence free survival (DRFS). 

Continue
SimBioSys June 16, 2023 ASCO 2023

Association of biophysics-based biomarker with tumor volumetric response in breast cancer treated with immunotherapy.

Using an integrative computational approach, we developed both the TumorIO biomarker and the TumorIO Score to predict response to IO therapy in breast cancer patients. Here, we assess the volumetric response in IO-treated patients and its relationship with the TumorIO Score. 

Continue
SimBioSys June 16, 2023 AACR 2023, Publications

Next generation immuno-oncology tumor profiling using a biophysics-based biomarker to predict immunotherapy response in early-stage breast cancer

Here, we applied an integrative computational approach to develop the IOScope biomarker, which predicts IO response in ESBC.

Continue
SimBioSys June 16, 2023 AACR 2023, Publications

A rapid, non-invasive test to determine HER2-low status in triple negative breast cancer (TNBC) patients

The potential to expand the current treatment for HER2-low and -zero patients, highlights the limitations of traditional HER2 assessment, including HER2 intra-tumoral heterogeneity, differential IHC pathology staining, and inter-reader variability. We therefore sought to address how to optimally identify HER2-low…

Continue
SimBioSys June 16, 2023 Bioinformatics advances, Publications

Computational speed-up of large-scale, single-cell model simulations via a fully integrated SBML-based format

Here, we developed two solutions to communication bottlenecks that speed-up simulation by ∼4-fold for hybrid stochastic-deterministic simulations and by over 100-fold for fully deterministic simulations.

Continue
SimBioSys June 16, 2023 BMC, Publications

Novel computational biology modeling system can accurately forecast response to neoadjuvant therapy in early breast cancer

Here, we perform a study in an independent cohort of early-stage and locally advanced breast cancer patients to forecast tumor response to NAT and assess the stability of a previously validated biophysical simulation platform.

Continue
SimBioSys June 16, 2023 Frontiers, Publications

Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer

Here, we perform a study in an independent cohort of early-stage and locally advanced breast cancer patients to forecast tumor response to NAT and assess the stability of a previously validated biophysical simulation platform.

Continue

Recent Posts

  • Validation of breast cancer quantitation from MRIs: Comparison of an AI-powered software with expert radiologists
  • Breast surgery: art or science? Survey of 36 experienced breast surgical oncologists 
  • SimBioSys Appoints Stacey Stevens as President and CEO 
  • Enabling Precision Surgery: Ricoh 3D for Healthcare and SimBioSys® to Explore Collaboration for Development of AI-Powered Personalized 3D-Printed Models
  • Precision Oncology Innovator SimBioSys® and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Recent Comments

No comments to show.

Archives

  • April 2025
  • January 2025
  • April 2024
  • January 2024
  • December 2023
  • November 2023
  • June 2023
  • December 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • December 2021
  • October 2021
  • May 2021
  • March 2021
  • October 2020
  • May 2020
  • March 2020
  • February 2020
  • January 2019
  • November 2018
  • October 2018
  • September 2017
  • August 2017
  • June 2017
  • March 2017
  • November 2016
  • June 2016
  • December 2015
  • October 2015
  • July 2015
  • March 2015
  • May 2014
  • February 2013

Categories

  • AACR 2022
  • AACR 2023
  • ACoP13
  • Articles
  • ASC publications
  • ASCO 2020
  • ASCO 2021
  • ASCO 2022
  • ASCO 2023
  • Bioinformatics advances
  • Biopharma Dealmakers AI issue
  • BMC
  • BMC
  • Business Wire
  • Cell NCI Symposium 2021
  • ESMO Breast Cancer 2022
  • Frontiers
  • ISMRM 2023
  • Life science boxes
  • News
  • NIH
  • Physical Review
  • PLOS
  • PNAS
  • Podcast
  • Press Releases
  • Publications
  • SABC 2023
  • SABCS 2019
  • SABCS 2021
  • SABCS 2022
  • Science Direct
  • SimBioSys
  • SITC 2022
  • Tech Tribune’s 2022
  • Whitepaper
  • Wired in
SimBioSys

SOLUTIONS

  • TumorSight Viz
  • TumorSight RISK
  • PhenoScope

RESOURCES

  • Publications
  • Abstracts
  • White Papers
  • Press Releases
  • News
  • Blogs
  • Articles

ABOUT

  • Technology
  • Our Company
  • Our Team
  • Careers
  • Contact Us

LEGAL

  • Terms of Service
  • Privacy Policy

©SimBioSys